Oramed Pharmaceuticals (ORMP)
(Real Time Quote from BATS)
$2.40 USD
0.00 (0.00%)
Updated Aug 30, 2024 02:06 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Oramed Pharmaceuticals Inc. [ORMP]
Reports for Purchase
Showing records 1 - 20 ( 81 total )
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Awaiting Pipeline Clarity; 1Q24 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Oral Drug Delivery Joint Venture; Debt Transaction; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Potential Hope for Oral Insulin; 1Q23 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Strategic Options Being Explored; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Phase 3 Failure; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Pivotal Data Readout Imminent; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Pivotal Top-Line Data Approaches; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Second Pivotal Oral Insulin Trial Reaches 50% Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Pipeline Update Underscores Near-Term Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Liver Disease-Focused European Patent Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
KOL Event Underscores ORMD-0801 Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Phase 2 NASH Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
2022 Outlook Promises Multiple Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Co-operation and Purchase Agreement With Vietnam-Based Firm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Oravax COVID-19 Vaccine Clinical Development Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Phase 3 Trial Progress; F2021 Financials; Raising PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Pipeline Advancing on Multiple Fronts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Phase 3 Program Patient Dosing Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R